^
Association details:
| Biomarker: | ASXL1 mutation |
|---|---|
| Cancer: | Myelodysplastic Syndrome |
| Drug: | alvocidib (DSP-2033) (CDK4 inhibitor, CDK6 inhibitor, CDK9 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
ASXL1 mutations are associated with a response to alvocidib and 5-azacytidine combination in myelodysplastic neoplasms
Published date:
11/02/2023
Excerpt:
In this study, we performed a comprehensive in vitro assessment of alvocidib and 5-AZA effects in n=45 high-risk MDS patients...Mutational profiling of MDS samples identified ASXL1 mutations as predictors of response...Overall, our study demonstrated augmented activity for the alvocidib + 5-AZA combination in higher-risk MDS and identified ASXL1 mutations as a biomarker of response for potential stratification studies.
Secondary therapy:
azacitidine
Source:
Title:
6257 - Mutations in the ASXL1 and ZRSR2 genes are associated with the response to the combination of alvocidib and 5-azacytidine in higher-risk myelodysplastic syndromes
Published date:
03/09/2022
Excerpt:
...we found significant associations between ASXL1 and ZRSR2 mutations and higher sensitivity of MDS samples to 5-Aza+Alv combination (p=0.008 and p=0.0005 in univariable analysis respectively)….Overall, we provide pre-clinical support for the use of 5-Aza+Alv combination for higher-risk MDS and identified ASXL1 and ZRSR2 mutations as potential genetic biomarkers of augmented response.
Secondary therapy:
azacitidine
